Ardelyx Shares Surge on Promising Clinical Trial Results
Investors are showing renewed confidence in Ardelyx following the release of compelling new clinical data for its treatment IBSRELA.
The pharmaceutical company presented these findings at the recent ACG congress, revealing that 88% of patients expressed satisfaction with their treatment regimen. Even more impressively, 95% of participants reported significant improvement in their constipation symptoms.
Significant Symptom Improvement Documented
A detailed post-hoc analysis demonstrated substantial therapeutic benefits across multiple symptom areas.
- Among IBS-C patients, 75% experienced reduced bloating
- 84% noted improved abdominal pain relief
- Over 70% of clinical trial subjects regained their ability to perform daily activities without restriction
No direct quote available in the given text.
Ardelyx shares surge due to positive trial results.
More News
- We need a new Turing test to assess AI’s real-world knowledge
- Opinion: Get Waymos off our streets - Washington Square News
- Rethinking human roles in AI warfare – Peace Research Institute Oslo (PRIO)
- Wizz Air reintroduces its “All You Can Fly” pass for unlimited travel!
- Pacific climate finance needs a paradigm shift
- 'Secretly they continue to live within us and through us' – Baptist News Global
- US passport support in Apple Wallet is a hugely important step
- Magistrates protest outside Parliament